ANRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Alto Neuroscience Inc (ANRO) is not a strong buy for a beginner investor with a long-term focus at this time. Despite a recent price increase and a bullish technical setup, the company's financial performance is weak, with declining net income and EPS. Additionally, there are no significant positive catalysts or proprietary trading signals to support immediate action. It is advisable to monitor the stock for better entry points or improved financial performance.
The stock shows a bullish trend with moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram of 0.263. RSI is neutral at 62.473, and the stock is trading near a resistance level of 19.589. However, the pre-market price dropped by -0.47%, indicating some selling pressure.
Analyst raised the price target to $28, citing the company's precision psychiatry approach and promising ALTO-101 trial. The stock has a bullish technical setup.
Hedge funds are selling the stock, with a 159.20% increase in selling activity last quarter. Financial performance is weak, with declining net income (-15.50% YoY) and EPS (-16.13% YoY). The company has no revenue growth and no significant insider trading trends.
In Q3 2025, revenue remained at $0 with no YoY growth. Net income dropped to -$14.18 million (-15.50% YoY), and EPS declined to -$0.52 (-16.13% YoY). Gross margin remained at 0%.
BTIG analyst Thomas Shrader raised the price target from $27 to $28 and maintained a Buy rating, highlighting the company's innovative approach to precision psychiatry and the potential of the ALTO-101 trial.
